Esperion Therapeutics, Inc.
ESPR
$2.51
-$0.21-7.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 92.93% | 5.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 92.93% | 5.98% | |||
| Cost of Revenue | -24.61% | 54.89% | |||
| Gross Profit | 297.21% | -31.57% | |||
| SG&A Expenses | -0.99% | 5.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.45% | 29.19% | |||
| Operating Income | 955.84% | -240.37% | |||
| Income Before Tax | 303.21% | -146.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 297.34% | -146.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 297.34% | -146.23% | |||
| EBIT | 955.84% | -240.37% | |||
| EBITDA | 958.34% | -239.47% | |||
| EPS Basic | 267.33% | -142.39% | |||
| Normalized Basic EPS | 272.23% | -142.18% | |||
| EPS Diluted | 239.21% | -142.39% | |||
| Normalized Diluted EPS | 243.24% | -142.18% | |||
| Average Basic Shares Outstanding | 17.91% | 1.61% | |||
| Average Diluted Shares Outstanding | 41.76% | 1.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||